Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2024

Annual Industry Ranking And Forecast

VIEW NOW

Featured Stories


Arcus And Gilead Make GI Cancers The Focus Of Their TIGIT Hopes

Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.

Companies Cancer Clinical Trials

Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease

Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.

Clinical Trials Business Strategies Research & Development

Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program

Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.

Financing Innovation StartUps and SMEs

Asia Spotlight

From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo

When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company? 

Leadership Strategy

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Executives On The Move: Changes At The Top At Ocuphire Pharma, YS Biopharma And More

Recent executive moves in the industry include new CEOs at Latigo Biotherapeutics and YS Biopharma Co, plus new directors at Cingulate.

Executive Changes Leadership

Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

South Korea Business Strategies

AbbVie Stays On Script With Michael As Next CEO

As previously indicated, AbbVie will go with an internal candidate, president and COO Robert Michael, to succeed Richard Gonzalez as CEO. The company has recently positioned Michael prominently.

Executive Changes Leadership

Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies

Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma. 

Sweden Emerging Company Profile
Interviews

Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

South Korea Business Strategies

Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies

Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma. 

Sweden Emerging Company Profile

From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo

When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company? 

Leadership Strategy

Sage Ready To Turn Over Cards On Bets Outside Of Depression

Sage has two postpartum depression drugs on the market, but will read out mid-stage trials this year for two candidates in Huntington’s, Parkinson’s and Alzheimer’s diseases and essential tremor.

Clinical Trials Strategy
See All
Graphics

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

Clinical Trials Commercial

Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth

Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.

Companies Deals

Biopharma’s Winners And Losers Of 2023: Obesity Drugs Reshape Big Pharma

Novo Nordisk and Eli Lilly kickstarted an obesity drug revolution in 2023, just as investors cooled on biopharma’s vaccine saviors as the world looked to move on from COVID-19.

Commercial Companies

Top 10 Best-Selling Drugs Of Q3 2023: Ozempic Challenges Humira As Keytruda Extends Leadership

As Merck & Co’s checkpoint inhibitor Keytruda further cemented its position at the top of the best-selling drugs list, biosimilar-challenged Humira sales fell once again. Meanwhile, Novo Nordisk’s diabetes injection Ozempic continued its ascent.

Market Intelligence Sales & Earnings
See All
Recent Stories

Blueprint RETreats As It Sells US Gavreto Rights To Rigel

After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.

Business Strategies Deals

Executives On The Move: Changes At The Top At Ocuphire Pharma, YS Biopharma And More

Recent executive moves in the industry include new CEOs at Latigo Biotherapeutics and YS Biopharma Co, plus new directors at Cingulate.

Executive Changes Leadership

ViiV’s Cabenuva Could Find Niche In Non-Adherent HIV Patients

The company said results of the LATITUDE trial showed superiority for the long-acting injectable over daily oral pills in patients struggling with adherence to their HIV treatment regimens.

Clinical Trials Infectious Diseases

Bausch + Lomb Dry Eye Franchise Ahead Of Growth Targets

Having acquired Xiidra from Novartis and getting US approval of Miebo in 2023, B+L’s two-product dry eye franchise delivered 66% year-over-year growth during Q4 2023.

Sales & Earnings Business Strategies

Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.

Clinical Trials Cardiovascular

BMS Looks For Krazati KRAS Lead After Amgen’s Stumble

Success in a confirmatory study and in combination with Keytruda could seal BMS’s best-in-class claims.

Companies Clinical Trials

Bayer Cuts Dividend To The Bone To Cut Debt

The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.

Business Strategies Restructuring

Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

South Korea Business Strategies

AbbVie Stays On Script With Michael As Next CEO

As previously indicated, AbbVie will go with an internal candidate, president and COO Robert Michael, to succeed Richard Gonzalez as CEO. The company has recently positioned Michael prominently.

Executive Changes Leadership

RAPT Therapeutics’ Lead Drug On Clinical Hold After Case Of Liver Failure

Zelnecirnon (RPT193), in Phase IIb for atopic dermatitis and Phase IIa for asthma, may not have caused the case of liver failure cited in the hold but the pause may impede a crucial data readout.

Clinical Trials Drug Safety

Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies

Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma. 

Sweden Emerging Company Profile

Stock Watch: Novo Edges Ahead Of Lilly In GLP-1 Agonist Battle

The sales performances of the GLP-1 agonists dominated the earnings of Novo Nordisk and Lilly, with both stocks hitting 52-week highs after their results. But one moved ahead of the other in an important strategic bottleneck.

Stock Watch Sales & Earnings
UsernamePublicRestriction

Register